<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Biotechnology - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcbiotechnol/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Biotechnology (ISSN 1472-6750) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/53"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/3/18"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/54"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/47"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/37"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/4/23"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/39"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/55"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/56"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/7/26"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/53">
            
            <title>Expression of HIV-1 antigens in plants as potential subunit vaccines</title>
			<description>Background:
Human immunodeficiency virus type 1 (HIV-1) has infected more than 40 million people worldwide, mainly in sub-Saharan Africa. The high prevalence of HIV-1 subtype C in southern Africa necessitates the development of cheap, effective vaccines. One means of production is the use of plants, for which a number of different techniques have been successfully developed. HIV-1 Pr55Gag is a promising HIV-1 vaccine candidate: we compared the expression of this and a truncated Gag (p17/p24) and the p24 capsid subunit in Nicotiana spp. using transgenic plants and transient expression via Agrobacterium tumefaciens and recombinant tobamovirus vectors. We also investigated the influence of subcellular localisation of recombinant protein to the chloroplast and the endoplasmic reticulum (ER) on protein yield. We partially purified a selected vaccine candidate and tested its stimulation of a humoral and cellular immune response in mice.
Results:
Both transient and transgenic expression of the HIV antigens were successful, although expression of Pr55Gag was low in all systems; however, the Agrobacterium-mediated transient expression of p24 and p17/p24 yielded best, to more than 1 mg p24/kg fresh weight. Chloroplast targeted protein levels were highest in transient and transgenic expression of p24 and p17/p24. The transiently-expressed p17/p24 was not immunogenic in mice as a homologous vaccine, but it significantly boosted a humoral and T cell immune response primed by a gag DNA vaccine, pTHGagC.
Conclusion:
Transient agroinfiltration was best for expression of all of the recombinant proteins tested, and p24 and p17/p24 were expressed at much higher levels than Pr55Gag. Our results highlight the usefulness of plastid signal peptides in enhancing the production of recombinant proteins meant for use as vaccines. The p17/p24 protein effectively boosted T cell and humoral responses in mice primed by the DNA vaccine pTHGagC, showing that this plant-produced protein has potential for use as a vaccine.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/53</link>		
			<dc:creator>Ann Meyers, Ereck Chakauya, Enid Shephard, Fiona L Tanzer, James Maclean, Alisson Lynch, Anna-Lise Williamson and Edward P Rybicki</dc:creator>
			<dc:source>BMC Biotechnology 2008, 8:53</dc:source>
			<dc:subject>Number of accesses: 845</dc:subject>
			<dc:date>2008-06-23</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-53</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>53</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/3/18">
            
            <title>Real-time PCR based on SYBR-Green I fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions</title>
			<description>Background:
Real-time PCR is increasingly being adopted for RNA quantification and genetic analysis. At present the most popular real-time PCR assay is based on the hybridisation of a dual-labelled probe to the PCR product, and the development of a signal by loss of fluorescence quenching as PCR degrades the probe. Though this so-called 'TaqMan' approach has proved easy to optimise in practice, the dual-labelled probes are relatively expensive.
Results:
We have designed a new assay based on SYBR-Green I binding that is quick, reliable, easily optimised and compares well with the published assay. Here we demonstrate its general applicability by measuring copy number in three different genetic contexts; the quantification of a gene rearrangement (T-cell receptor excision circles (TREC) in peripheral blood mononuclear cells); the detection and quantification of GLI, MYC-C and MYC-N gene amplification in cell lines and cancer biopsies; and detection of deletions in the OPA1 gene in dominant optic atrophy.
Conclusion:
Our assay has important clinical applications, providing accurate diagnostic results in less time, from less biopsy material and at less cost than assays currently employed such as FISH or Southern blotting.</description>
			<link>http://www.biomedcentral.com/1472-6750/3/18</link>		
			<dc:creator>Frederique Ponchel, Carmel Toomes, Kieran Bransfield, Fong T Leong, Susan H Douglas, Sarah L Field, Sandra M Bell, Valerie Combaret, Alain Puisieux, Alan J Mighell, Philip A Robinson, Chris F Inglehearn, John D Isaacs and Alex F Markham</dc:creator>
			<dc:source>BMC Biotechnology 2003, 3:18</dc:source>
			<dc:subject>Number of accesses: 811</dc:subject>
			<dc:date>2003-10-13</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-3-18</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2003-10-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/54">
            
            <title>Three-dimensional culture of human meniscal cells: Extracellular matrix and proteoglycan production</title>
			<description>Background:
The meniscus is a complex tissue whose cell biology has only recently begun to be explored. Published models rely upon initial culture in the presence of added growth factors. The aim of this study was to test a three-dimensional (3D) collagen sponge microenvironment (without added growth factors) for its ability to provide a microenvironment supportive for meniscal cell extracellular matrix (ECM) production, and to test the responsiveness of cells cultured in this manner to transforming growth factor-&#946; (TGF-&#946;).
Methods:
Experimental studies were approved prospectively by the authors' Human Subjects Institutional Review Board. Human meniscal cells were isolated from surgical specimens, established in monolayer culture, seeded into a 3D scaffold, and cell morphology and extracellular matrix components (ECM) evaluated either under control condition or with addition of TGF-&#946;. Outcome variables were evaluation of cultured cell morphology, quantitative measurement of total sulfated proteoglycan production, and immunohistochemical study of the ECM components chondroitin sulfate, keratan sulfate, and types I and II collagen.Result and ConclusionMeniscal cells attached well within the 3D microenvironment and expanded with culture time. The 3D microenvironment was permissive for production of chondroitin sulfate, types I and II collagen, and to a lesser degree keratan sulfate. This microenvironment was also permissive for growth factor responsiveness, as indicated by a significant increase in proteoglycan production when cells were exposed to TGF-&#946; (2.48 &#956;g/ml &#177; 1.00, mean &#177; S.D., vs control levels of 1.58 &#177; 0.79, p &lt; 0.0001). Knowledge of how culture microenvironments influence meniscal cell ECM production is important; the collagen sponge culture methodology provides a useful in vitro tool for study of meniscal cell biology.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/54</link>		
			<dc:creator>Helen E Gruber, David Mauerhan, Yin Chow, Jane A Ingram, H James Norton, Edward N Hanley and Yubo Sun</dc:creator>
			<dc:source>BMC Biotechnology 2008, 8:54</dc:source>
			<dc:subject>Number of accesses: 679</dc:subject>
			<dc:date>2008-06-26</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-54</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>54</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/47">
            
            <title>A kinetic-based sigmoidal model for the polymerase chain reaction and its application to high-capacity absolute quantitative real-time PCR</title>
			<description>Background:
Based upon defining a common reference point, current real-time quantitative PCR technologies compare relative differences in amplification profile position. As such, absolute quantification requires construction of target-specific standard curves that are highly resource intensive and prone to introducing quantitative errors. Sigmoidal modeling using nonlinear regression has previously demonstrated that absolute quantification can be accomplished without standard curves; however, quantitative errors caused by distortions within the plateau phase have impeded effective implementation of this alternative approach.
Results:
Recognition that amplification rate is linearly correlated to amplicon quantity led to the derivation of two sigmoid functions that allow target quantification via linear regression analysis. In addition to circumventing quantitative errors produced by plateau distortions, this approach allows the amplification efficiency within individual amplification reactions to be determined. Absolute quantification is accomplished by first converting individual fluorescence readings into target quantity expressed in fluorescence units, followed by conversion into the number of target molecules via optical calibration. Founded upon expressing reaction fluorescence in relation to amplicon DNA mass, a seminal element of this study was to implement optical calibration using lambda gDNA as a universal quantitative standard. Not only does this eliminate the need to prepare target-specific quantitative standards, it relegates establishment of quantitative scale to a single, highly defined entity. The quantitative competency of this approach was assessed by exploiting "limiting dilution assay" for absolute quantification, which provided an independent gold standard from which to verify quantitative accuracy. This yielded substantive corroborating evidence that absolute accuracies of &#177; 25% can be routinely achieved. Comparison with the LinReg and Miner automated qPCR data processing packages further demonstrated the superior performance of this kinetic-based methodology.
Conclusion:
Called "linear regression of efficiency" or LRE, this novel kinetic approach confers the ability to conduct high-capacity absolute quantification with unprecedented quality control capabilities. The computational simplicity and recursive nature of LRE quantification also makes it amenable to software implementation, as demonstrated by a prototypic Java program that automates data analysis. This in turn introduces the prospect of conducting absolute quantification with little additional effort beyond that required for the preparation of the amplification reactions.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/47</link>		
			<dc:creator>Robert G Rutledge and Don Stewart</dc:creator>
			<dc:source>BMC Biotechnology 2008, 8:47</dc:source>
			<dc:subject>Number of accesses: 472</dc:subject>
			<dc:date>2008-05-08</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-47</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>47</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-08</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/37">
            
            <title>Killing cancer cells by targeted drug-carrying phage nanomedicines</title>
			<description>Background:
Systemic administration of chemotherapeutic agents, in addition to its anti-tumor benefits, results in indiscriminate drug distribution and severe toxicity. This shortcoming may be overcome by targeted drug-carrying platforms that ferry the drug to the tumor site while limiting exposure to non-target tissues and organs.
Results:
We present a new form of targeted anti-cancer therapy in the form of targeted drug-carrying phage nanoparticles. Our approach is based on genetically-modified and chemically manipulated filamentous bacteriophages. The genetic manipulation endows the phages with the ability to display a host-specificity-conferring ligand. The phages are loaded with a large payload of a cytotoxic drug by chemical conjugation. In the presented examples we used anti ErbB2 and anti ERGR antibodies as targeting moieties, the drug hygromycin conjugated to the phages by a covalent amide bond, or the drug doxorubicin conjugated to genetically-engineered cathepsin-B sites on the phage coat. We show that targeting of phage nanomedicines via specific antibodies to receptors on cancer cell membranes results in endocytosis, intracellular degradation, and drug release, resulting in growth inhibition of the target cells in vitro with a potentiation factor of >1000 over the corresponding free drugs.
Conclusion:
The results of the proof-of concept study presented here reveal important features regarding the potential of filamentous phages to serve as drug-delivery platform, on the affect of drug solubility or hydrophobicity on the target specificity of the platform and on the effect of drug release mechanism on the potency of the platform. These results define targeted drug-carrying filamentous phage nanoparticles as a unique type of antibody-drug conjugates.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/37</link>		
			<dc:creator>Hagit Bar, Iftach Yacoby and Itai Benhar</dc:creator>
			<dc:source>BMC Biotechnology 2008, 8:37</dc:source>
			<dc:subject>Number of accesses: 457</dc:subject>
			<dc:date>2008-04-03</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-37</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>37</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/4/23">
            
            <title>Use of polyethyleneimine polymer in cell culture as attachment factor and lipofection enhancer</title>
			<description>Background:
Several cell lines and primary cultures benefit from the use of positively charged extracellular matrix proteins or polymers that enhance their ability to attach to culture plates. Polyethyleneimine is a positively charged polymer that has gained recent attention as a transfection reagent. A less known use of this cationic polymer as an attachment factor was explored with several cell lines.
Results:
Polyethyleneimine compared favorably to traditional attachment factors such as collagen and polylysine. PC-12 and HEK-293 cells plated on dishes coated with polyethyleneimine showed a homogeneous distribution of cells in the plate, demonstrating strong cell adhesion that survived washing procedures. The polymer could also be used to enhance the adherence and allow axonal outgrowth from zebrafish retinal explants. The effects of this coating agent on the transfection of loosely attaching cell lines were studied. Pre-coating with polyethyleneimine had the effect of enhancing the transfection yield in procedures using lipofection reagents.
Conclusion:
Polyethyleneimine is an effective attachment factor for weakly anchoring cell lines and primary cells. Its use in lipofection protocols makes the procedures more reliable and increases the yield of expressed products with commonly used cell lines such as PC-12 and HEK-293 cells.</description>
			<link>http://www.biomedcentral.com/1472-6750/4/23</link>		
			<dc:creator>Ajith R Vancha, Suman Govindaraju, Kishore VL Parsa, Madhuri Jasti, Maribel Gonz&#225;lez-Garc&#237;a and Rafael P Ballestero</dc:creator>
			<dc:source>BMC Biotechnology 2004, 4:23</dc:source>
			<dc:subject>Number of accesses: 442</dc:subject>
			<dc:date>2004-10-15</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-4-23</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>23</prism:startingPage>
					
			
							
					<prism:publicationDate>2004-10-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/39">
            
            <title>Electrospun micro- and nanofiber tubes for functional nervous regeneration in sciatic nerve transections</title>
			<description>Background:
Although many nerve prostheses have been proposed in recent years, in the case of consistent loss of nervous tissue peripheral nerve injury is still a traumatic pathology that may impair patient's movements by interrupting his motor-sensory pathways. In the last few decades tissue engineering has opened the door to new approaches;: however most of them make use of rigid channel guides that may cause cell loss due to the lack of physiological local stresses exerted over the nervous tissue during patient's movement. Electrospinning technique makes it possible to spin microfiber and nanofiber flexible tubular scaffolds composed of a number of natural and synthetic components, showing high porosity and remarkable surface/volume ratio.
Results:
In this study we used electrospun tubes made of biodegradable polymers (a blend of PLGA/PCL) to regenerate a 10-mm nerve gap in a rat sciatic nerve in vivo. Experimental groups comprise lesioned animals (control group) and lesioned animals subjected to guide conduits implantated at the severed nerve stumps, where the tubular scaffolds are filled with saline solution. Four months after surgery, sciatic nerves failed to reconnect the two stumps of transected nerves in the control animal group. In most of the treated animals the electrospun tubes induced nervous regeneration and functional reconnection of the two severed sciatic nerve tracts. Myelination and collagen IV deposition have been detected in concurrence with regenerated fibers. No significant inflammatory response has been found. Neural tracers revealed the re-establishment of functional neuronal connections and evoked potential results showed the reinnervation of the target muscles in the majority of the treated animals.
Conclusion:
Corroborating previous works, this study indicates that electrospun tubes, with no additional biological coating or drug loading treatment, are promising scaffolds for functional nervous regeneration. They can be knitted in meshes and various frames depending on the cytoarchitecture of the tissue to be regenerated. The versatility of this technique gives room for further scaffold improvements, like tuning the mechanical properties of the tubular structure or providing biomimetic functionalization. Moreover, these guidance conduits can be loaded with various fillers like collagen, fibrin, or self-assembling peptide gels or loaded with neurotrophic factors and seeded with cells. Electrospun scaffolds can also be synthesized in different micro-architectures to regenerate lesions in other tissues like skin and bone.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/39</link>		
			<dc:creator>Silvia Panseri, Carla Cunha, Joseph Lowery, Ubaldo Del Carro, Francesca Taraballi, Stefano Amadio, Angelo Vescovi and Fabrizio Gelain</dc:creator>
			<dc:source>BMC Biotechnology 2008, 8:39</dc:source>
			<dc:subject>Number of accesses: 413</dc:subject>
			<dc:date>2008-04-11</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-39</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>39</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/55">
            
            <title>Analysis of Transient Phosphorylation-Dependent Protein-Protein Interactions in Living Mammalian Cells Using Split-TEV</title>
			<description>Background:
Regulated protein-protein interactions (PPIs) are pivotal molecular switches that are important for the regulation of signaling processes within eukaryotic cells. Cellular signaling is altered in various disease conditions and offers interesting options for pharmacological interventions. Constitutive PPIs are usually mediated by large interaction domains. In contrast, stimulus-regulated PPIs often rely mainly on small posttranslational modifications and are thus better suited targets for drug development. However, the detection of modification-dependent PPIs with biochemical methods still remains a labour- and material-intensive task, and many pivotal PPIs potentially suited for pharmacological perturbation most likely remain to be identified. Therefore, the availability of methods to easily identify and quantify stimulus-dependent, potentially also transient, interaction events is essential. These assays should be applicable to intact mammalian cells, optimally also to primary cultured ones.
Results:
In this study, we adapted the split-TEV system to quantify phosphorylation-dependent and transient PPIs that occur in the cytosol of living mammalian cells. Split-TEV is based on a PPI-induced functional complementation of two previously inactive TEV protease fragments fused to interaction partners of choice. Genetically encoded transcription-coupled and proteolysis-only TEV reporter systems were used to transfer the reconstituted TEV activity into an easily quantifiable readout. We measured the phosphorylation-dependent interaction between the pro-apoptotic protein Bad and the adapter proteins 14-3-3 and  in NIH-3T3 fibroblasts and in primary cultured neurons. Using split-TEV assays, we show that Bad specifically interacts with 14-3-3 isoforms when phosphorylated by protein kinase Akt-1/PKB at Ser136. We could simultaneously determine the anti-apoptotic effect of the Bad/14-3-3 interactions in the same assay. Finally, we measured the phosphorylation-dependent Bad/14-3-3 interactions mediated by endogenous and transient Akt-1 activity. 
Conclusion:
Split-TEV assays are well suited to measure phosphorylation-dependent and transient PPIs that occur specifically in the cytosol of heterologous and primary cultured mammalian cells. Given the high sensitivity of the split-TEV system, all assays were performed in multi-plate formats and could be adapted for higher throughput to screen for pharmacologically active substances.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/55</link>		
			<dc:creator>Michael C Wehr, Lisa Reinecke, Anna Botvinnik and Moritz J Rossner</dc:creator>
			<dc:source>BMC Biotechnology 2008, 8:55</dc:source>
			<dc:subject>Number of accesses: 397</dc:subject>
			<dc:date>2008-07-13</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-55</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>55</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/56">
            
            <title>Successful elimination of non-neural cells and unachievable elimination of glial cells by means of commonly used cell culture manipulations during differentiation of GFAP and SOX2-positive neural progenitors (NHA) to neuronal cells

</title>
			<description>Background:
Although extensive research has been performed to control differentiation of neural stem cells - still, the response of those cells to diverse cell culture conditions often appears to be random and difficult to predict. To this end, we strived to obtain stabilized protocol of NHA cells differentiation - allowing for an increase in percentage yield of neuronal cells.
Results:
Uncommitted GFAP and SOX2 positive neural progenitors - so-called, Normal Human Astrocytes (NHA) were differentiated in different environmental conditions to: only neural cells consisted of neuronal [MAP2+, GFAP-] and glial [GFAP+, MAP2-] population, non-neural cells [CD44+, VIMENTIN+, FIBRONECTIN+, MAP2-, GFAP-, S100beta-, SOX2-], or mixture of neural and non-neural cells. 
In spite of successfully increasing the percentage yield of glial and neuronal vs. non-neural cells by means of environmental changes, we were not able to increase significantly the percentage of neuronal (GABA-ergic and catecholaminergic) over glial cells under several different cell culture testing conditions. Supplementing serum-free medium with several growth factors (SHH, bFGF, GDNF) did not radically change the ratio between neuronal and glial cells - i.e., 1,1:1 in medium without growth factors and 1,4:1 in medium with GDNF, respectively. 
Conclusions:
We suggest that biotechnologists attempting to enrich in vitro neural cell cultures in one type of cells - such as that required for transplantology purposes, should consider the strong limiting influence of intrinsic factors upon extracellular factors commonly tested in cell culture conditions. </description>
			<link>http://www.biomedcentral.com/1472-6750/8/56</link>		
			<dc:creator>Monika Witusik, Sylwester Piaskowski, Krystyna Hulas-Bigoszewska, Magdalena Zakrzewska, Sylwia M Gresner, Ausim S Azizi, Barbara Krynska, Pawel P Liberski and Piotr Rieske</dc:creator>
			<dc:source>BMC Biotechnology 2008, 8:56</dc:source>
			<dc:subject>Number of accesses: 360</dc:subject>
			<dc:date>2008-07-19</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-56</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>56</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/7/26">
            
            <title>Isolation of mesenchymal stem cells from equine umbilical cord blood</title>
			<description>Background:
There are no published studies on stem cells from equine cord blood although commercial storage of equine cord blood for future autologous stem cell transplantations is available. Mesenchymal stem cells (MSC) have been isolated from fresh umbilical cord blood of humans collected non-invasively at the time of birth and from sheep cord blood collected invasively by a surgical intrauterine approach. Mesenchymal stem cells isolation percentage from frozen-thawed human cord blood is low and the future isolation percentage of MSCs from cryopreserved equine cord blood is therefore expectedly low. The hypothesis of this study was that equine MSCs could be isolated from fresh whole equine cord blood.
Results:
Cord blood was collected from 7 foals immediately after foaling. The mononuclear cell fraction was isolated by Ficoll density centrifugation and cultured in a DMEM low glucose based media at 38.5&#176;C in humidified atmosphere containing 5% CO2. In 4 out of 7 samples colonies with MSC morphology were observed. Cellular morphology varied between monolayers of elongated spindle-shaped cells to layered cell clusters of cuboidal cells with shorter cytoplasmic extensions. Positive Alizarin Red and von Kossa staining as well as significant calcium deposition and alkaline phosphatase activity confirmed osteogenesis. Histology and positive Safranin O staining of matrix glycosaminoglycans illustrated chondrogenesis. Oil Red O staining of lipid droplets confirmed adipogenesis.
Conclusion:
We here report, for the first time, the isolation of mesenchymal-like stem cells from fresh equine cord blood and their differentiation into osteocytes, chondrocytes and adipocytes. This novel isolation of equine cord blood MSCs and their preliminary in vitro differentiation positions the horse as the ideal pre-clinical animal model for proof-of-principle studies of cord blood derived MSCs.</description>
			<link>http://www.biomedcentral.com/1472-6750/7/26</link>		
			<dc:creator>Thomas G Koch, Tammy Heerkens, Preben D Thomsen and Dean H Betts</dc:creator>
			<dc:source>BMC Biotechnology 2007, 7:26</dc:source>
			<dc:subject>Number of accesses: 332</dc:subject>
			<dc:date>2007-05-30</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-7-26</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>26</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
